Title
Category
Credits
Event date
Cost
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer after basal cell carcinoma (BCC) (Alam 2018).  The incidence of cSCC in the United States and throughout the world is increasing (Alam 2018).  In the US, each year 200,000-400,000 new cases of cSCC are expected, with disease-related death occurring in more than 3000 people with cSCC (Alam 2018).  Risk factors for cSCC include chronic sun exposure, advanced age, sensitive skin to UV radiation, and immunosuppression (Kabir 2018; Migden 2018).
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
During this Masterclass, expert faculty will discuss the links between sleep disorders and cardiometabolic health, as well as practical approaches for screening, referral, or treatment.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
The advent of SGLT-2 inhibitors and GLP-1 RAs to address cardiorenal risk in patients with and without type 2 diabetes, has opened up new avenues of prevention and treatment. However, individualizing the vast amount of evidence to patient care remains challenging. During this case, you will have a chance to explore treatment decisions to decrease overall cardiorenal risk in a complex patient, accompanied by expert commentary and brief review of evidence with SGLT-2is and GLP-1 RAs across cardiovascular outcomes trials.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Osteoporosis is a prevalent condition and a major health problem, but particularly more in postmenopausal women. Approximately 2 million osteoporosis-related fractures occur annually in the US, and more than 70% of these occur in women. Furthermore, osteoporosis carries a significant burden, estimated to be at $57 billion in 2018 and projected to reach more than $95 billion by year 2040.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Diabetic kidney disease (DKD) remains one of the major causes of morbidity and mortality in patients with type 2 diabetes. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including targeting mineralocorticoid receptor overactivation with novel, non-steroidal mineralocorticoid receptor antagonists (MRAs).
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.

Pages